公开(公告)号：US20140163032A1

公开(公告)日：2014-06-12

申请号：US14182994

申请日：2014-02-18

申请人： BRADLEY TEEGARDEN ,  Dennis Chapman ,  Marc Decaire ,  Peter I. Dosa ,  Konrad Feichtinger ,  HONNAPPA JAYAKUMAR ,  THUY-ANH Tran ,  Sonja Strah-Pleynet ,  Jay Xu

发明人： BRADLEY TEEGARDEN ,  Dennis Chapman ,  Marc Decaire ,  Peter I. Dosa ,  Konrad Feichtinger ,  HONNAPPA JAYAKUMAR ,  THUY-ANH Tran ,  Sonja Strah-Pleynet ,  Jay Xu

IPC分类号： C07D207/335 ,  C07D207/34 ,  C07D417/12 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D405/12

CPC分类号： C07D231/12 ,  A61K31/415 ,  C07D207/335 ,  C07D207/34 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

摘要翻译： 本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板聚集，冠状动脉疾病，心肌梗死，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

公开(公告)号：US20120295938A1

公开(公告)日：2012-11-22

申请号：US13417030

申请日：2012-03-09

申请人： BRADLEY TEEGARDEN ,  DENNIS CHAPMAN ,  MARC DECAIRE ,  PETER I. DOSA ,  KONRAD FEICHTINGER ,  HONNAPPA JAYAKUMAR ,  THUY-ANH TRAN ,  SONJA STRAH-PLEYNET ,  JAY XU

发明人： BRADLEY TEEGARDEN ,  DENNIS CHAPMAN ,  MARC DECAIRE ,  PETER I. DOSA ,  KONRAD FEICHTINGER ,  HONNAPPA JAYAKUMAR ,  THUY-ANH TRAN ,  SONJA STRAH-PLEYNET ,  JAY XU

IPC分类号： A61K31/415 ,  C07D405/12 ,  C07D231/12 ,  C07D413/12 ,  C07D403/12 ,  C07D417/12 ,  A61K31/422 ,  A61K31/454 ,  A61K31/427 ,  A61K31/4155 ,  A61P7/02 ,  A61P9/10 ,  A61P11/06 ,  A61P25/00 ,  A61P25/18 ,  C07D401/12

CPC分类号： C07D231/12 ,  A61K31/415 ,  C07D207/335 ,  C07D207/34 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

摘要翻译： 本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板聚集，冠状动脉疾病，心肌梗死，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

公开(公告)号：US20070010671A1

公开(公告)日：2007-01-11

申请号：US10551431

申请日：2004-03-30

申请人： Yoshinori Sekiguchi ,  Kosuke Kanuma ,  Katsunori Omodera ,  Tsuyoshi Busujima ,  Thuy-Anh Tran ,  Sangdon Han ,  Martin Casper ,  Bryan Kramer

发明人： Yoshinori Sekiguchi ,  Kosuke Kanuma ,  Katsunori Omodera ,  Tsuyoshi Busujima ,  Thuy-Anh Tran ,  Sangdon Han ,  Martin Casper ,  Bryan Kramer

IPC分类号： C07D403/02 ,  C07D239/94

CPC分类号： C07D239/95 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12

摘要： The present invention relates to novel compounds of Formula (1): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

摘要翻译： 本发明涉及新的式（1）化合物：其作为MCH受体拮抗剂。 这些组合物可用于药物组合物，其用途包括改善记忆功能，睡眠和觉醒，焦虑，抑郁，情绪障碍，癫痫发作，肥胖症，糖尿病，食欲和进食障碍，心血管疾病，高血压，血脂异常，心肌梗塞， 包括贪食症，厌食症，包括躁狂抑郁症，精神分裂症，del妄，痴呆，压力，认知障碍，注意力缺陷障碍，药物滥用障碍和包括帕金森氏病，癫痫和成瘾在内的运动障碍的暴饮暴食症。

公开(公告)号：US20140235622A1

公开(公告)日：2014-08-21

申请号：US14166511

申请日：2014-01-28

申请人： Bradley Teegarden ,  Dennis Chapman ,  Juyi Choi ,  Konrad Feichtinger ,  Sangdon Han ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Jay Xu ,  Ning Zou

发明人： Bradley Teegarden ,  Dennis Chapman ,  Juyi Choi ,  Konrad Feichtinger ,  Sangdon Han ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Jay Xu ,  Ning Zou

IPC分类号： C07D417/12 ,  C07D401/12 ,  C07D231/16 ,  C07D413/12 ,  C07D403/12 ,  C07D409/12 ,  C07D405/12 ,  C07D231/12

CPC分类号： A61K31/415 ,  C07D231/12 ,  C07D231/16 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

摘要翻译： 本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

公开(公告)号：US08148418B2

公开(公告)日：2012-04-03

申请号：US12301180

申请日：2007-05-17

申请人： Bradley Teegarden ,  Dennis Chapman ,  Marc Decaire ,  Peter I. Dosa ,  Konrad Feichtinger ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Sonja Strah-Pleynet ,  Jay Xu

发明人： Bradley Teegarden ,  Dennis Chapman ,  Marc Decaire ,  Peter I. Dosa ,  Konrad Feichtinger ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Sonja Strah-Pleynet ,  Jay Xu

IPC分类号： A61K31/415 ,  C07D231/12 ,  A61P25/24

CPC分类号： C07D231/12 ,  A61K31/415 ,  C07D207/335 ,  C07D207/34 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

摘要翻译： 本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

公开(公告)号：US20090197935A1

公开(公告)日：2009-08-06

申请号：US12301172

申请日：2007-05-17

申请人： Bradley Teegarden ,  Dennis Chapman ,  Juyi Choi ,  Konrad Feichtinger ,  Sangdon Han ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Jingdong Xu ,  Ning Zou

发明人： Bradley Teegarden ,  Dennis Chapman ,  Juyi Choi ,  Konrad Feichtinger ,  Sangdon Han ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Jingdong Xu ,  Ning Zou

IPC分类号： A61K31/415 ,  C07D231/12 ,  A61P25/24

CPC分类号： A61K31/415 ,  C07D231/12 ,  C07D231/16 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

摘要翻译： 本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板聚集，冠状动脉疾病，心肌梗死，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

公开(公告)号：US20090186895A1

公开(公告)日：2009-07-23

申请号：US12301180

申请日：2007-05-17

申请人： Bradley Teegarden ,  Dennis Chapman ,  Marc Decaire ,  Peter I. Dosa ,  Konrad Feichtinger ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Sonja Strah-Pleynet ,  Jingdong Xu

发明人： Bradley Teegarden ,  Dennis Chapman ,  Marc Decaire ,  Peter I. Dosa ,  Konrad Feichtinger ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Sonja Strah-Pleynet ,  Jingdong Xu

IPC分类号： A61K31/5377 ,  C07D231/12 ,  A61K31/415 ,  C07D413/12 ,  A61K31/422 ,  C07D401/12 ,  A61K31/454 ,  C07D403/12 ,  A61K31/4196 ,  C07D417/12 ,  A61K31/427 ,  C07D405/12 ,  A61K31/4155 ,  A61K31/41 ,  A61P11/06 ,  A61P3/10 ,  A61P7/02 ,  A61P29/00 ,  A61P25/00 ,  A61P9/12

CPC分类号： C07D231/12 ,  A61K31/415 ,  C07D207/335 ,  C07D207/34 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

摘要翻译： 本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

公开(公告)号：US08680119B2

公开(公告)日：2014-03-25

申请号：US13417030

申请日：2012-03-09

申请人： Bradley Teegarden ,  Dennis Chapman ,  Marc Decaire ,  Peter I. Dosa ,  Konrad Feichtinger ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Sonja Strah-Pleynet ,  Jingdong Xu

发明人： Bradley Teegarden ,  Dennis Chapman ,  Marc Decaire ,  Peter I. Dosa ,  Konrad Feichtinger ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Sonja Strah-Pleynet ,  Jingdong Xu

IPC分类号： C07D231/12 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

CPC分类号： C07D231/12 ,  A61K31/415 ,  C07D207/335 ,  C07D207/34 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

摘要翻译： 本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板聚集，冠状动脉疾病，心肌梗死，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

公开(公告)号：US08664258B2

公开(公告)日：2014-03-04

申请号：US13417028

申请日：2012-03-09

申请人： Bradley Teegarden ,  Dennis Chapman ,  Juyi Choi ,  Konrad Feichtinger ,  Sangdon Han ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Jay Xu ,  Ning Zou

发明人： Bradley Teegarden ,  Dennis Chapman ,  Juyi Choi ,  Konrad Feichtinger ,  Sangdon Han ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Jay Xu ,  Ning Zou

IPC分类号： A61K31/415 ,  C07D231/00

CPC分类号： A61K31/415 ,  C07D231/12 ,  C07D231/16 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

摘要翻译： 本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。

公开(公告)号：US08148417B2

公开(公告)日：2012-04-03

申请号：US12301172

申请日：2007-05-17

申请人： Bradley Teegarden ,  Dennis Chapman ,  Juyi Choi ,  Konrad Feichtinger ,  Sangdon Han ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Jingdong Xu ,  Ning Zou

发明人： Bradley Teegarden ,  Dennis Chapman ,  Juyi Choi ,  Konrad Feichtinger ,  Sangdon Han ,  Honnappa Jayakumar ,  Thuy-Anh Tran ,  Jingdong Xu ,  Ning Zou

IPC分类号： A61K31/415 ,  C07D231/12 ,  A61P25/24

CPC分类号： A61K31/415 ,  C07D231/12 ,  C07D231/16 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

摘要翻译： 本发明涉及某些调节5-HT2A 5-羟色胺受体活性的式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板聚集，冠状动脉疾病，心肌梗死，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体相关疾病的方法。